{"id":"W2924379719","doi":"10.1093/annonc/mdz046","title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":157,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi-Sankyo; Prospect Creek Foundation; Agios Pharmaceuticals; Bayer Fund; Bristol-Myers Squibb; FUJIFILM Pharmaceuticals U.S.A.; Genentech; Ovarian Cancer Research Fund; Valeant Pharmaceuticals International; Comprehensive Cancer Center, City of Hope; Takeda Pharmaceuticals U.S.A.; Comprehensive Cancer Center, University of Chicago Medical Center; Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; Illumina; National Cancer Institute; AbbVie; Novartis; AstraZeneca; National Institutes of Health; Breast Cancer Research Foundation; U.S. Department of Defense; Boehringer Ingelheim; Pfizer","keywords":"KRAS; Concordance; Genotyping; Medicine; Lung cancer; Digital polymerase chain reaction; Liquid biopsy; COLD-PCR; Genotype; ROS1; Cell-free fetal DNA; Cancer research; Oncology; Cancer; Internal medicine; Mutation; Gene; Point mutation; Biology; Adenocarcinoma; Genetics; Polymerase chain reaction; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001481776,0.0001060034,0.000208369,0.00003060192,0.00002695235,0.000006565706,0.0001997379,0.000124373,0.00001828295],"category_scores_gemma":[0.0001378235,0.00008732889,0.00004175302,0.00007551763,0.00006989916,0.00000985588,0.00005041336,0.00007720573,0.000001683026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008545075,"about_ca_system_score_gemma":0.000465483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008256926,"about_ca_topic_score_gemma":0.001963339,"domain_scores_codex":[0.9990717,0.00005092106,0.0003316416,0.0002622275,0.0001022226,0.0001812959],"domain_scores_gemma":[0.9989228,0.0001189033,0.0003184411,0.0003936398,0.0002118539,0.00003438287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001630491,0.0001205501,0.01176015,0.00001793327,0.00006898076,0.00000119573,0.0003638947,0.0293626,0.9528947,0.0000283474,0.001360467,0.002390648],"study_design_scores_gemma":[0.007144822,0.003236792,0.02648011,0.00003140394,0.00003236228,9.157299e-7,0.0005504573,0.0006927499,0.9408032,0.00005902753,0.0207222,0.0002459126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961891,0.0004651465,0.00003438255,0.0002724814,0.0001955752,0.0003135493,0.000344768,0.000002017427,0.002183043],"genre_scores_gemma":[0.9978235,0.0007246302,0.000367182,0.0004328713,0.0001018896,0.0000149592,0.0004701598,0.00001280898,0.00005195243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02866985,"threshold_uncertainty_score":0.3561169,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02871166766124892,"score_gpt":0.2654595750996026,"score_spread":0.2367479074383536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}